



# Euro BioFairs Compass

Winter 2014

## Guide to Life Sciences **Events**



**SPECIAL**

8<sup>th</sup> Berlin Conference on IP in Life Sciences

# Natural Products



**27 February 2015, 9.30 a.m., Embassy of South Africa, Berlin, Germany**

The Berlin Conference on IP in Life Sciences has become a must-attend for life sciences decision makers, IP and legal experts, business developers and investors. The upcoming event focuses on natural compounds, their business potential and the most recent legal effects of the implementation of the Nagoya Protocol.

- › Natural Compounds – Business Cases and Potentials
- › Biodiversity – From Collections to Research Co-Operations
- › Patents, Legal Aspects – Implementing the Nagoya Protocol
- › Natural Compounds 2.0 – Synthetic Biology, Opportunities and Legal Aspects
- › Best Practices in Business and Research Alliances
- › Use of Genes and Genomes – Ethical Aspects

Please register now at [www.biocom.de/events/IP](http://www.biocom.de/events/IP) or send an email to [events@biocom.de](mailto:events@biocom.de)  
 Restricted capacity!

Sponsors:



Supporting Partner:



Media Partner:



# Planning the grand tour

**EUROBIOFAIRS COMPASS** Every manager, scientist or business developer has their own set of events marked in red on the calendar, and once the tinsel and trees have been cleared away, the spring conference season comes knocking. That's why now is a great time to start making plans to hit your personal favourites, but also to consider widening your scope and checking out a new event!



The 9<sup>th</sup> edition of BIO-Europe Spring offers the chance to experience Paris in all its springtime glory. That is, of course, if you can manage to tear yourself away from the partnering event, where you'll find the crème de la crème of European biotechnology. Naturally, you can combine one with the other and organise a meeting at the Île Saint Germain, which is close to the Parc des Expositions at the Porte de Versailles. If you want to attend, book now so you don't miss the boat. Early registration for the 9–11 March event closes on 20 January.

## Keep your suitcase packed

A second highlight is the Forum Life Science. Like the BIO-Europe Spring, it is going on for the 9<sup>th</sup> time. But the Forum has a longer history, as it is only held biannually, and was originally initiated back in 1999. Since then, the congress in Munich has evolved into an event that involves 1,000 participants. While the focus in Paris is on the business side, in Munich you

will find all the new technologies to take your own ideas to another level. The event takes place on 11–12 March, allowing you to reap the fruits of both worlds over one extended weekend. And why not? The suitcases are packed anyway.

A week later, on 19–20 March, all clinical research whiz-kids should prick up their ears – and head to Berlin. Learn how to improve your workflow in an ever-changing environment at the Annual Congress on Pharmaceutical Medicine. Update your knowledge on various topics such as the EU clinical trial regulation, life-cycle management and much more.

Biotech aficionados that think big should block off the days from 13 April onwards. At the International Conference on bio-based materials in Cologne, experience at first hand exactly how an established market is being reshaped by visionaries from the chemicals and plastics businesses.

For those in the healthcare sector, a second visit to Paris might be unavoidable. This year's DIA annual EuroMeeting

on 13–15 April will attract 2,500 stakeholders, all interested in health product development. With the DIA Clinical Forum and the Clinical Forum Exhibition under one roof, the Palais de Congrès is certain to turn into a global healthcare village.

A smaller event that still has a major impact kicks off on 14 April in Basel. The Swiss city will host the nation's most important biotech event, the Swiss Biotech Day. As in previous years, the new Swiss biotech report will shine a light on the industry's status in the country. For those who may need an extra push – Novartis CEO Joseph Jimenez is slated to give the keynote lecture.

The weather in late spring also makes travelling to the UK an attractive option. If you do, make sure to visit the 13<sup>th</sup> EGA-European Biosimilars Group Conference in London. Held on 23–24 April, this is where all the big names of this highly regulated field will be. You're guaranteed to leave with your questions answered and your imagination stirred.

One of the hottest topics not yet in biomedicine but already in drug development will be in the limelight from 21–22 April. Experts from all over the world will present the latest applications of stem-cell disease models and 3D organoids at the 8<sup>th</sup> International Meeting of the Stem Cell Network NRW in Bonn. It's a must for biopharma professionals.

Finally, make sure to visit Frankfurt before heading off to your summer holidays. On 15–19 June, key global bioeconomy players will gather at Biobased-World, the industrial biotech congress atACHEMA, the world's most important stage for chemical engineering. ■





9<sup>th</sup> ANNUAL INTERNATIONAL PARTNERING CONFERENCE  
**BIO-EUROPE  
 SPRING® 2015**

**9–11 March, 2015**  
**Parc des Expositions de Paris**  
**Porte de Versailles, Paris, France**

# Heading to Paris

**BIO-EUROPE SPRING** The 9<sup>th</sup> annual BIO-Europe Spring international partnering conference will be held in France next March at the Paris expo Porte de Versailles exhibition centre. Decisionmakers will be on hand to access in-licensing and investment opportunities through partnering, with an emphasis on one-to-one, private business development and discovery meetings.

BIO-Europe Spring is a key date for companies and participants across the life science value chain, from large biotech and pharma firms to financiers and innovative start-ups. The event has one of the largest and most dynamic platforms in the sector, with a reputation for facilitating industry partnering.

The leading pharmaceutical companies that help sponsor the event send teams of scouts to BIO-Europe Spring to engage with new and innovative products,

ideas and companies. Past sponsors include industry giants AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Merck Serono, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shire, Takeda and many others.

“We are very excited to bring BIO-Europe Spring to Paris for the first time,” says Anna Chrisman, Group Managing Director of EBD Group. “The French capital is a world-class research destination with an impressive

network of leading research hospitals and start-ups. There is already a lot of buzz around the springtime event, and we expect the quality and variety of attending companies to be very high. This translates into more partnering opportunities and more potential deals.”

## Where visionaries seek partners

Company presentations are the lifeblood of the event, and they bring global innovators and visionaries together with potential partners. BIO-Europe Spring also features a diverse range of industry leaders speaking on panels and workshops.

The 2014 event boasted 10,780 scheduled one-to-one meetings, with 2,115 licensing opportunities posted from among 1,209 companies that attended. Top numbers in the current economy, where partnering remains a core drug development strategy for both Big Pharma and biotech. ■

## World-changing alliances



**GREETING** With a focus on collaboration opportunities and dealmaking, BIO-Europe Spring® 2015 is key to business strategy for global biotech,

pharma and investors. Paris is a world-class research destination with an impressive network of leading research hospitals and start-ups. The event brings a huge range of high-quality companies to present licensing opportunities directly to potential partners, and leads to alliances that quite literally change the world. See you in Paris in the spring!

**Anna Chrisman**  
 EBD Group  
 Group Managing Director

## QUICK FACTS

### REGISTRATION

Early registration until 20 January, 2015. Companies with three full-paying delegates will receive one complimentary ticket for the fourth attendee from that company.

### MORE INFORMATION

[www.ebdgroup.com/bes/](http://www.ebdgroup.com/bes/)  
 Phone: +49 89 2388 7560

MARK YOUR CALENDAR!

9TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE

# BIO-EUROPE SPRING® 2015

**MARCH 9-11, 2015**  
**PARIS, FRANCE**  
Paris Expo - Porte de Versailles

BIO-Europe Spring® is the leading springtime life science partnering event in Europe providing companies with high caliber partnering opportunities.

**January 20, 2015** - Early registration deadline

**January 26, 2015** - Online Partnering opens

Find out more: [www.ebdgroup.com/bes](http://www.ebdgroup.com/bes)

Produced by

**EBD**GROUP

Supported by





11-12 March, 2015  
Garching campus of the TU  
München, Munich, Germany

# Innovations for life

**FORUM LIFE SCIENCE** An event that brings representatives from industry and academia together, the Forum Life Science has been a leading interdisciplinary platform for knowledge transfer and cooperation in Europe since 1999. Participants this year will discuss emerging trends in fields as diverse as Pharma Development, Food & Nutrition and Industrial Biotechnology.

The latest findings and developments in the life sciences will be in focus at the 9<sup>th</sup> International Forum Life Science Congress taking place at the Technische Universität München in Garching on the 11-12 March, where participants will learn more about their implementation in innovative technologies and new products in areas such as pharmaceuticals, food and biotechnology. Cell Therapies

and Immuno-Oncology, Personalised Nutrition and Future Food Trends are just some of the hot topics that will be in the limelight there. Renewable Resources, Biobased Products and Urban Mining will also be discussed as topics within Industrial Biotechnology.

Held biannually, this congress conceived and organised by Bayern Innovativ GmbH is a central meeting point and platform for the exchange of information and the development of cross-industry contacts in nearly every area of the life sciences.

We expect around 1,000 participants from 20 countries to take part in the event, among them about 60 international experts presenting current trends and the latest findings. They'll be joined by more than 100 exhibitors. In addition, the German Life Science Award will be granted at a Plenary Session taking place on 11 March. A reception planned for the evening of the same day will provide an excellent opportunity for networking. ■

## Future solutions

**GREETING** *In the face of future challenges, novel technologies and solutions are needed to help prevent and treat conditions like cancer, infections or diabetes, in novel targeted nutritional concepts for infants or elderly people, as well as for the efficient use of limited resources.*



*These challenges can only be addressed by partners who collaborate across different disciplines and industry sectors. Along with innovative technologies for bioprocess engineering and the utilisation of biogenic resources, the latest research results and developments in genomics, metabolomics and synthetic biology offer great opportunities.*

*The 9<sup>th</sup> International Forum Life Science Congress is a meeting point that brings together experts from the biosciences, engineering, food sciences and medicine with companies from the biotech, pharma, food, chemical and materials sectors. This platform helps establish novel contacts for cooperations across fields at the international level, generating ideas for innovative technologies, products and services.*

**Dr. Matthias Konrad**  
Head of Material | Life Science  
Bayern Innovativ

### QUICK FACTS

#### People

1,000 participants are expected in total, including 60 speakers and 100 exhibitors

#### Venue


The Garching campus of the TU München, Munich

Phone: +49 911-20671-125  
[www.bayern-innovativ.de/fls2015en](http://www.bayern-innovativ.de/fls2015en)



9<sup>th</sup> International Congress and Exhibition

# Forum Life Science



**Pharma  
Development**



**Food &  
Nutrition**



**Industrial  
Biotechnology**

**11 – 12 March 2015**

Technische Universität München, Garching

**Information and registration:**

[www.bayern-innovativ.de/fls2015](http://www.bayern-innovativ.de/fls2015)



**13–15 April, 2015**  
**Maternushaus Cologne**  
**Germany**

# The bio-based best

**CONFERENCE ON BIO-BASED MATERIALS** Slated to take place from 13–15 April 2015 in Cologne (Germany), the 8<sup>th</sup> International Conference on Bio-based Materials will bring an estimated 250 participants and 30 exhibitors up to speed on the latest developments in this up-and-coming field.

This year's conference is aimed at providing major players from the European and Asian bio-based chemicals, plastics and composite industries with an opportunity to present and discuss their latest developments and strategies. Along with its attendant exhibition, the event will bring together newcomers and experts with leading companies in the sector.

One goal is to address innovative developments in the industry, with presentations focused on areas like bio-based

3D printing and microplastics in the environment, along with their sources, impacts and current feasible solutions. Bioplastics and building blocks are key drivers of innovative and sustainable development in the economy and industry as a whole, and growing numbers of companies are entering the field. The latest news on operational biorefineries will also be a big draw at the conference. Alongside leading companies, representatives from political bodies and as-

sociations will be on hand at the event, since strengthening the bio-based economy requires the right regulatory framework. That's why another focus will be the latest national and regional policies, strategies and visions.

The Innovation Award Ceremony is another highlight at the event. The "Bio-based Material of the Year 2015" is awarded to innovative young bio-based chemicals and materials industry actors who have launched new bio-based products on the market. Conference participants will choose the three winners.

After last year's great success, the conference will for the second time include a third day specifically dedicated to start-ups presenting groundbreaking innovations. In cooperation with prestigious partners, conference organiser nova-Institute is set to provide a perfect platform and meeting point for networking between start-ups, established companies and investors. ■

## Get sustainable

**GREETING** The 8<sup>th</sup> International Conference on Bio-based Materials in Cologne is one of the biggest events on bio-based chemicals, plastics and composites in Europe. This year we expect 250 participants and 30 exhibitors to attend. Leading companies will



be on hand presenting both operational biorefineries and new bio-based materials. A special highlight will be the participant selection of the "Bio-based Material of the Year 2015".

To exchange the latest information and network with the industrial leaders in the sector, join us at the 8<sup>th</sup> International Conference on Bio-based Materials!

**Michael Carus**  
 CEO  
 nova-Institute

## QUICK FACTS

### Online Registration

[www.bio-based.eu/conference](http://www.bio-based.eu/conference)

### Contact

Dominik Vogt  
[dominik.vogt@nova-institut.de](mailto:dominik.vogt@nova-institut.de)

### Venue

Maternushaus  
 Kardinal-Frings-Str. 1–3  
 50668 Cologne



# 8<sup>th</sup> International Conference on Bio-based Materials

13–15 April 2015, Maternushaus, Cologne, Germany

**Special Topics: Bio-based 3D Printing – 3<sup>rd</sup> Day Dedicated to High-Potential Start-Ups**



**HIGHLIGHTS FROM EUROPE AND ASIA:**

**BIO-BASED PLASTICS AND COMPOSITES – BIOREFINERIES AND INDUSTRIAL BIOTECHNOLOGY**

This conference aims to provide major players from the European and Asian bio-based chemicals, plastics and composite industries with an opportunity to present and discuss their latest developments and strategies. Representatives of political bodies and associations will also have their say alongside leading companies. Due to the huge response for the second time the conference will count with a third day especially dedicated to start-ups.

The 8th International Conference on Bio-based Materials (“Biowerkstoff-Kongress”) builds on successful previous conferences: More than 200 participants and 20 exhibitors mainly from industry are expected!

**PRELIMINARY PROGRAMME: HIGHLIGHTS OF EUROPEAN AND ASIAN LEADING COUNTRIES IN BIO-BASED ECONOMY**

**1<sup>st</sup> Day (13 April 2015): Policy and Industry**

- Policy and markets
- Commercial biorefineries
- Innovation Award “Bio-based Material of the Year 2015”

**2<sup>nd</sup> Day (14 April 2015): Industry**

- Biopolymers and building blocks
- Bio-based 3D printing
- Microplastics in the environment: Sources, impacts and solutions

**3<sup>rd</sup> Day (15 April 2015): Start-Ups**

- Start-ups with partners

**Entrance Fee**

Conference incl. Catering, plus 19 % VAT

1 <sup>st</sup> Day Conference 8 April 2014	2 <sup>nd</sup> Day Conference 9 April 2014	3 <sup>rd</sup> Day Conference 10 April 2014
475 €	425 €	400 €
775 €		
	725 €	
950 (+ exhibition booth if desired - limited offer)		

**Venue & Accomodation**

Maternushaus Cologne, Germany  
Kardinal-Frings-Str. 1–3, 50668 Cologne  
+49 (0)221 16310 | info@maternushaus.de

**Contact**



**Dominik Vogt**  
Exhibition, Partners,  
Media partners, Sponsors  
+49 (0)2233 4814-49  
dominik.vogt@nova-institut.de

20 Free Exhibition Booths  
for Registered Participants.  
Register now at:



[www.bio-based.eu/conference](http://www.bio-based.eu/conference)



Organiser



[www.nova-institute.eu](http://www.nova-institute.eu)

**Your versatile platform for information on bio-based economy**

Services of the nova-Institute GmbH:

Conferences | bio-based News | Publications | Market Research





19–20 March, 2015  
Hotel Meliã,  
Berlin, Germany

# No pitfalls. Success!

**31<sup>ST</sup> ANNUAL CONGRESS ON PHARMACEUTICAL MEDICINE** Clinical research for new pharmaceuticals and medical devices is becoming more and more complex. It is increasingly important to avoid pitfalls early on when designing such projects. At this congress, key issues for clinical research planning and problem solving will be addressed.

This year's event will shine a light on how clinical research might look in 2020. Subheaded "Increasing Complexity Among Medical Innovation and Reimbursement", the congress boasts six symposia with 20 expert-to-expert presentations and a lively, versatile, practice-oriented dialogue between industry representatives, service providers, authorities, ethics committees, academia, and congress participants.

## Right decisions at the right time

Criteria for go/no-go decisions have to be defined as early as possible in clinical research, ideally in Phase I. This also frequently comprises the decision whether or not, and when, to gain a partner or to sell an auspicious development project. Later on in Phase III, the trial has to be mastered to generate sufficient data for the stretch between product approval, reimbursement, and price negotiations. For better planning and executing clinical trials, you will learn at the 31<sup>st</sup> Annual Congress on Pharmaceutical Med-

icine about new paths and how to face new challenges.

Moreover, increasingly complex regulations put high demands on all parties involved and on the organisation and structure of clinical research overall. This continually involves the principles of good clinical practice in clinical research and, most recently, has posed the question: "Can quality in clinical research projects emerge from monitoring or audits?" You can expect answers to this question at this congress.

## Data protection and drug-device combinations

Data protection is also an issue of good clinical practice. In this regard, the current changes to European data protection legislation are of high relevance for clinical research, and will also be addressed and discussed at the congress. Another topic is the development of fixed drug-device combination products. The specific requirements demanded will be discussed as well. ■

## Framing solutions

**GREETING** *Complexity among research and reimbursement for new pharmaceuticals and medical devices is one of the greatest challenges for the process of medical innovation. At the 31<sup>st</sup> Annual Congress on Pharmaceutical Medicine, we will analyse these challenges, shape different scenarios, discuss the complexity and frame solutions. On behalf of the DGPharMed as the host and of the programme committee, we kindly invite you to attend this congress. We look forward to welcoming you on 19–20 March, 2015 in Berlin for an active dialogue. The programme is available at [www.dgpharmed.de/veranstaltungen](http://www.dgpharmed.de/veranstaltungen).*



### Dr. Axel Mescheder

DGPharMed

Board Chairman, Congress President

## QUICK FACTS

### SYMPOSIA HIGHLIGHTS

EU Clinical Trial Regulation 2016, Drug-Device Combination Products, Benefit-Cost Ratio, Life-Cycle Management

### REGISTRATION

[info@dgpharmed.de](mailto:info@dgpharmed.de)

Early-bird rate until 16 January, 2015





# 31<sup>st</sup> DGPharMed Annual Meeting

**Clinical Research 2020: Increasing complexity between  
medical innovation and reimbursement?**

March 19–20, 2015 · Berlin, Germany

### Symposia

- » Clinical trials with medical devices – Today and tomorrow
- » Early clinical development – Set the course early
- » Development of complex medical devices & drug device combination products
- » Interaction of regulatory strategies, cost-benefit assessment & life-cycle-management
- » EU Regulation 2016: New regulation – New challenges
- » Why do clinical trials fail?

*Please note: the official conference language will be German*

### Conference Venue

Hotel Meliã · Friedrichstraße 103 · 10117 Berlin · [www.melia.com/Berlin](http://www.melia.com/Berlin)

### Congress fees

*Early-Bird-rates until February 6<sup>th</sup>, 2015*      *Booking from February 7<sup>th</sup>, 2015*

Members: ..... 490,- €      Members: ..... 590,- €

Non-Members: ..... 640,- €      Non-Members: ..... 740,- €

### Organizing Committee

Stefan Busch, Mathias Klümper,  
Axel Mescheder, Daniel Sehr

### Further information

[info@dgpharmed.de](mailto:info@dgpharmed.de)  
[www.dgpharmed.de](http://www.dgpharmed.de)

Interested in  
exhibition space?  
Please contact  
[aussteller@  
degepe.eu](mailto:aussteller@degepe.eu)



You will find the complete program  
flyer enclosed in this publication!  
or online at [www.dgpharmed.de](http://www.dgpharmed.de)





**DIA** DEVELOP  
INNOVATE  
ADVANCE

13–15 April, 2015  
Palais de Congrès  
Paris, France

# Boosting the best

**DIA EUROMEETING 2015** The DIA EuroMeeting has always been a significant date in the agenda of health product development professionals. It is widely recognised as the leading event for networking and knowledge transfer through the development value chain.

To help professionals keep pace with the rapidly changing regulatory environment, the DIA EuroMeeting is changing too. In 2015, it will share a venue with the DIA Clinical Forum as well as the Clinical Forum Exhibition. This will bring more than 2,500 potential contacts under a single roof. With three days of opportunities to

learn, connect and build partnerships, the DIA EuroMeeting is cementing its place in the product development calendar.

## New challenges, new opportunities

DIA has always played a vital role in maintaining the skills and network of health product development professionals. That need is more pressing than ever. New understanding of disease processes, new regulatory approaches, and the increasing influence of information technology is accelerating and diversifying healthcare innovation.

How professionals react to this challenge will be vital. Embracing this opportunity will build upon Europe's status as a hub for healthcare innovation, stimulating further investment. However, all stakeholders have a role to play in creating an environment where research and regulation are mutually supportive. This means providing effective platforms for discussion and knowledge transfer.

DIA, with more than 18,000 members, is the perfect organisation to provide these platforms. It has an enviable track record in bringing together innovators, regulators and influencers.

## Creating a Global Healthcare Village

This is why the DIA EuroMeeting 2015 is the ideal opportunity to equip all businesses with the knowledge and network to prepare for these future challenges, wherever they sit in the value chain. The meeting is based around 12 highly topical and relevant themes. Headline topics include the new clinical trial legislation, regulatory coordination and the impact of Big Data on healthcare.

However, DIA Meetings offer more than listening and learning; they are a community. The EuroMeeting provides a unique microcosm of the health product development environment; three days of high-quality networking and knowledge exchange. The 2015 EuroMeeting brings further refinements.

By combining the DIA EuroMeeting and the Clinical Forum Exhibition into a single site, it will turn the Palais de Congrès in Paris into a Global Healthcare Village. With more than 2,500 stakeholders in one place, no other conference offers such a comprehensive array of stakeholders and fellow experts spanning the entire healthcare value chain.

## QUICK FACTS

### HIGHLIGHTS

- › 12 highly relevant, topical themes
- › A microcosm of the health product development community
- › More than 2,500 stakeholders under one roof
- › Relevant throughout the value chain

### CONTACT

Phone +41 61 225 51 51  
www.diahome.org



# 27th DIA Annual EuroMeeting

13-15 April 2015 | Palais des Congrès | Paris

**Development, Innovation, Access and Patient Safety**

Healthcare innovation is accelerating and diversifying to meet the demands posed by societal change. The impact on your business environment is equally dramatic. The shift to patient-centric business models is already revolutionising how we do business in Europe

- How can you keep your professional knowledge up to speed?
- How do you ensure that your network is up to date?
- How will you identify and meet the right partners in your company's innovation value chain?

**Find the answers to these challenges - and many more - at the DIA EuroMeeting 2015.**

The DIA EuroMeeting 2015 offers you a microcosm of the evolving European healthcare landscape, built around three days of high-quality networking, partnering and knowledge transfer opportunities.

- 12 highly relevant, thought-leading themes
- Contacts, networking and solutions - all on a single site
- New for 2015: DIA EuroMeeting and the Clinical Forum Exhibition in a single venue.
- More than 2,500 health product development professionals at a single venue

Meet the individuals who can provide the answers to your challenges: Professionals in the pharmaceutical and biotech industries, CROs, clinical trial sites, health regulatory agencies and delegates from academia and patient organisations and many more.

Visit [www.diahome.org/EM2015](http://www.diahome.org/EM2015) for more information



**DIA** DEVELOP  
INNOVATE  
ADVANCE

DIA Europe, Middle East and Africa  
Kuechengasse 16  
4051 Basel, Switzerland



**SWISS**   
**BIOTECH**™

**14 April, 2015**  
**Congress Center Basel**  
**Basel, Switzerland**

# At the hub of biotech

**SWISS BIOTECH DAY** One Nation, One Cluster – nowhere does the truth of this Swiss claim grow more apparent than at the Swiss Biotech Day. For the 17<sup>th</sup> year running, the event will offer a high-caliber meeting point for top-ranking representatives from the Central European life science sector.

Driven by the general assembly of the Swiss Biotech Association (SBA), Switzerland's leading biotech conference brings together more than 350 senior executives from the country's biotech companies and senior scientists from leading academic institutions.

Organised jointly by BIOCOM AG and the SBA, the event's 2015 programme starts off with a bang: the keynote address will be held by no other than Novartis CEO Joseph Jimenez, one of the

most influential leaders the biopharmaceutical industry has to offer. Another highlight on the agenda is the presentation of the Swiss Biotech Report 2015.

In the afternoon, four different parallel sessions – presented by partners of the Swiss Biotech Day – will offer insights into more specific issues within the life sciences. The "Analyst & Investor" track will focus on the analyses and predictions of publicly listed

biotech companies. The track "Innovation in Healthcare" – traditionally one of the livelier sessions – will feature biotech startups presenting new therapeutic approaches. The "Service" track will be of interest to businesses new and old. Here, updates on regulatory affairs go hand in hand with presentations by CROs and CMOs. Last but not least, the Switzerland Global Enterprises-led track "Hotbeds in Biotechnology Globally" is of particular interest as it draws a comparison and discussion of leading regions and clusters in Biotech.

Due to the success of last year's event, in 2015 the Swiss Biotech Day will relocate to the Congress Center in Basel, which has long been a life-science cluster. As always, the event targets entrepreneurs, investors, research-units, analysts, political decision-makers and additional industry stakeholders. ■

## Biotech is Science and Business



**Welcome** Thank you to our stakeholders. Now in its 17<sup>th</sup> year, the SwissBiotech™ Day is a solid agenda point in the industry. The day gets bigger every year

*and now it is Basel's turn to welcome biotechnology, an important driver of the life-science for economic well-being nationally and internationally. SBA members meet up for the Annual General Assembly and enjoy interesting topics throughout the day. Attendees will have unique opportunities to meet with old friends and make new ones. We look forward to seeing you there.*

**Domenico Alexakis**  
CEO  
Swiss Biotech Association

### QUICK FACTS

#### Highlights

- › Keynotes by industry authorities
- › Swiss biotech report 2015
- › In-depth parallel sessions
- › One-on-one partnerings

#### Contact


Swiss Biotech Association  
Phone +41-43-508-1121

[www.swissbiotechday.ch](http://www.swissbiotechday.ch)



# SWISS BIOTECH DAY 2015

The leading Swiss Biotech Conference and Annual General Assembly of the Swiss Biotech Association



Switzerland's leading biotech conference brings together more than 350 senior executives from biotech companies across Europe and senior scientists from leading academic institutions.

Highlights of the conference will be the keynote address by Novartis CEO Joseph Jimenez and the presentation of the Swiss Biotech Report 2015.

In the afternoon, partners of the Swiss Biotech Day will present the following parallel tracks: Analyst & Investor, Innovations in Healthcare, Regulatory Affairs, Hotbeds in Biotech.

More information on the conference, the complete agenda and a registration form can be found on: [www.swissbiotechday.ch](http://www.swissbiotechday.ch)



14 APRIL 2015

Congress Center Basel

Organised by:



**BIOCOM AG**

in cooperation with:



Departement für Wirtschaft, Soziales und Umwelt des Kantons Basel-Stadt  
**Amt für Wirtschaft und Arbeit**



Supporting Partner:



Media Partner:





\_8th International Meeting  
\_2015 Bonn

21–22 April, 2015  
Plenary Chamber, World CC,  
Bonn, Germany

# Stem cell innovators

**STEM CELL NETWORK NRW** The 8<sup>th</sup> International Meeting of the Stem Cell Network NRW looks forward to presenting thorough coverage of current topics such as disease modelling, stem cell-derived organoids and pluripotent stem cells. Thanks to the support from the state of North Rhine-Westphalia, attending this first-class congress will be free of charge.

Modelling diseases with the help of patient-derived iPS cells is a promising field that could lead not only to understanding disease pathologies but also to cell-based treatments. Fred Gage (La Jolla), the opening speaker at the 8<sup>th</sup> International Meeting, is using cell models to understand neurological and psychological diseases. Gage's lab has shown that, contrary to accepted dogma, human beings are capable of growing new nerve

cells throughout life (neurogenesis), and he is working to understand how these cells can be induced to become mature, functioning nerve cells in the adult brain and spinal cord.

Rick Livesey (Cambridge) is also working on neurological diseases by investigating the cerebral cortex. His group is focusing on Down's syndrome and Alzheimer's disease, whereas his colleague Ludovic Vallier is differentiating pluripo-

tent cell sources into hepatocytes and pancreatic Islet cells – different cell types relevant for clinical applications. Another long-held belief that human cloning and hence the extraction of pluripotent stem cells from human blastocysts is impossible, was proven wrong by Shoukhrat Mitalipov (Portland) in 2013. In Bonn, he will explain his vision of using those cells for future therapeutic approaches.

One possible progression from using (pluripotent) cells to model diseases is establishing 3D organoids to illuminate the whole range of pathologies accompanying a disease, or using those models to test drug candidates. Clare Blackburn and Jürgen Knoblich will explain how they have managed to grow a 'mini-thymus' and 'mini-brains' respectively.

The organisers particularly welcome junior scientists who wish to participate in the programme with scientific posters and discuss their results at Meet the Expert sessions. ■

## Meeting of minds

**WELCOME** With its inaugural Meeting twelve years ago, the Stem Cell Network NRW established Germany's first internationally orientated congress on stem cell research. In 2015, the focus of the congress will be on modelling functional organs, stem-cell engineering and the

specification of stem cells. There will also be talks on disease modelling and therapeutic approaches, showing how the field has entered the translational phase. This year we look forward to welcoming Clare Blackburn, Fred Gage, Jürgen Knoblich, Shoukhrat Mitalipov, Hiromitsu Nakauchi, Thomas Zwaka and many other outstanding speakers.

**Ira Herrmann**  
Managing Director  
Stem Cell Network NRW




## QUICK FACTS

### HIGHLIGHTS

- > 600+ participants
- > Poster presentation
- > Company exhibition
- > Meet the Expert sessions
- > Free access

### REGISTRATION

Phone: +49 211 8964043  
folke-sabel@stammzellen.nrw.de  
www.congress.stemcells.nrw.de



# 8th International Meeting

Stem Cell Network  
North Rhine-Westphalia

**April 21 – 22, 2015**  
**Bonn, Germany**

**Congress attendance is free of charge.**

**Please register at:**  
**[www.congress.stemcells.nrw.de](http://www.congress.stemcells.nrw.de)**

**funded by:**

Ministry of Innovation, Science  
and Research of the German State  
of North Rhine-Westphalia



- Sessions on Self Organization of Stem Cells, Neural Development and Stem Cells & Therapeutic Approaches
- Opening Lecture by Fred Gage
- Lectures by Clare Blackburn, Juergen Knoblich, Ron McKay, Shoukhrat Mitalipov, Ludovic Vallier and many more
- Poster Session, abstract submission due by March 1, 2015
- Company Exhibition
- Satellite Symposium on Bioinformatics



Stem Cell Network  
North Rhine Westphalia





23–24 April, 2015  
Grange Tower Bridge Hotel  
London, UK

# Biosimilars update

**EGA** Leading biosimilars experts will meet next 23–24 April in the British capital for the 13<sup>th</sup> EGA-European Biosimilars Group Conference.

The key theme of the conference will be the science of extrapolation of indications, which is at the heart of the biosimilar medicines debate. As every year, we will have the privilege of hearing and interacting with key regulators from the EMA Biosimilar Medicinal Products Working Party, thereby bringing the biosimilarity concept closer to patients, medical societies and other healthcare professionals. Following the successful launches in 2014 of the GfK study on factors supporting a sustainable European biosimilar medicines market, we will continue the debate of its findings in a multi-stakeholder set-

ting. Further 2015 highlights are the current status and the future outlook of the biological and biosimilar medicines market, the European Commission industrial policy strategy and follow-up on the “Tajani initiative”. We will also gain insight into biosimilars market access and its evolving landscape, sharing best practices with key EU member states and Real World Evidence supporting biosimilars uptake. Another plenary highlight features the European experience on the biosimilars naming and labelling regime and the latest status of the proposed WHO Biological Qualifier Scheme, which has gained

momentum. Traditionally, we also cover the EMA update on biosimilar medicines approvals and the latest developments in the European scientific guidelines, as well as the role of the WHO and worldwide National Drug Regulatory Authorities in consolidating a framework facilitating biosimilars global development. And as at past events, we again expect the direct participation of the US/FDA, providing the audience with a unique opportunity to gain insights into the very latest and most interesting developments in the US.

The conference brings together representatives from National and International Regulatory Agencies, Pricing & Reimbursement Authorities, Academia, Patient Organisations, Medical Societies, Healthcare Professionals, Chief Executives, Executive Directors, Vice Presidents, Heads, Team Leaders and Managers from the Biopharmaceutical Industry, as well as Analysts, Consultants, Service Providers and many more. ■

## Join a key event!

**GREETING** *On behalf of the European Biosimilars Group and the EGA, I kindly invite you to join us for EBG Biosimilars 2015, the 13<sup>th</sup> EGA-European Biosimilars Group Conference. Over the years, this event has become the annual gathering of the world's leading biosimilars experts, attracting Drug Regu-*



*latory Authorities, Academia, Healthcare Professionals and Industry representatives from all over the globe. The international conference provides a unique opportunity to hear and learn from leading experts in the biosimilars space, discuss current key topics, and get an update of the latest regulatory and market developments. I look forward to welcoming you in London!*

**Suzette Kox**

Senior Director Scientific Affairs, EGA/Coordinator European Biosimilars Group

## QUICK FACTS

**Registration**

[www.egaevents.org](http://www.egaevents.org)

**Contact**

Lucia Romagnoli  
[events@degenerics.com](mailto:events@degenerics.com)

**Venue**

Grange Tower Bridge Hotel  
45 Prescott Street  
London, E1 8GP

# LONDON

23-24 April 2015

Grange Tower Bridge Hotel

EUROPEAN GENERIC  
MEDICINES ASSOCIATION  
[www.egagenerics.com](http://www.egagenerics.com)



## EBG BIOSIMILARS 2015

### 13<sup>th</sup> EGA-EUROPEAN BIOSIMILARS GROUP CONFERENCE

Join the 13<sup>th</sup> EGA-European Biosimilars Group Conference and increase your knowledge of this very promising field. Over the years, this event has become the annual gathering of the world's leading biosimilars experts, attracting Drug Regulatory Authorities, Academia, Healthcare Professionals and Industry representatives from all around the globe.

This international conference provides a unique opportunity to hear and learn from leading experts in the biosimilars space, to discuss the current key topics, to get an update of the latest regulatory and market developments as well as to network with colleagues and new contacts during one of the networking events in London.

#### WHO SHOULD ATTEND

National and international Regulatory Agencies / Pricing & Reimbursement Authorities / Academia / Patient Organisations / Medical Societies / Healthcare Professionals / Analysts / Consultants and Service Providers / Chief Executives, Executive Directors, Vice Presidents, Heads, Team Leaders and Managers from the Pharmaceutical Industry in the following departments: Commercial Affairs and Strategic Planning; Regulatory Affairs; Drug Safety & Risk Management; Medical Affairs; Legislation and Policy Advice

And many more

#### FEEDBACK FROM ATTENDEES IN 2014:

*"It was indeed an informative meeting, with impressive international participation."*

*"This is to say how very useful I found my attendance at the 12<sup>th</sup> International Conference on Biosimilars."*

*"It was an extremely interesting program, with very good speakers and panels."*

*"Very good and a very well organized meeting."*

*"Congrats for this excellent meeting."*

#### ABOUT THE EUROPEAN BIOSIMILARS GROUP (EBG):

The European Biosimilars Group (EBG), a sector group of the EGA, represents the leading companies in the biosimilar medicines space. The EBG Members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

#### KEY TOPIC: The science of extrapolation of indications, explained by EU regulators

- Biological and biosimilar medicines market: current status and future outlook
- Biosimilars: the European Commission industrial policy strategy and "Tajani initiative" follow-up
- Biosimilars evolving landscape: insight into market access
- Biosimilars uptake: best practice sharing by key EU member states
- Debate on GfK study findings: a multi-stakeholder approach in support of the biosimilar medicines market sustainability
- Real World Evidence sharing
- The science of extrapolation of indications, explained by EU regulators
- Biosimilars naming and labelling regime: the European experience
- WHO Biological Qualifier Scheme: status of the proposal
- Biosimilar medicines approvals and scientific guidelines latest developments: the EMA overview
- Biosimilars global development: WHO and National Drug Regulatory Authorities role
- Biosimilars: news from the US/FDA
- The biosimilarity concept: bringing it closer to patients, healthcare professionals and medical societies

#### FOR FURTHER INFORMATION & TO REGISTER ONLINE

Please visit [www.egaevents.org](http://www.egaevents.org) or [www.egagenerics.com](http://www.egagenerics.com) or contact Lucia Romagnoli:

E: [events@egagenerics.com](mailto:events@egagenerics.com) | M: +44-7562-876873

To book one of the sponsorship packages or for more information contact [trudy@egaevents.org](mailto:trudy@egaevents.org)

EVENT  
SPONSOR





## ACHEMA 2015

15–19 June, 2015  
Messe Frankfurt  
Frankfurt am Main/Germany

# Focus on bioeconomy

**ACHEMA** AICHEMA 2015 will once again be the hub of the process industries from 15 to 19 June, when 3,800 exhibitors and 170,000 visitors from all around the world meet in Frankfurt/Main. With the chemical industry shifting from fossil to renewable resources, one of the focal topics of the congress is BiobasedWorld.

Biobased chemicals are present in our daily lives but go mostly unnoticed, and their number is growing. Many of the regular exhibitors at AICHEMA are already part of the bioeconomy with no further fanfare. Their modesty does them credit, but BiobasedWorld's concern is to make a fuss, to raise awareness and to put biobased processes and products into the limelight of the exhibition.

Partnering and congress are other important elements of Biobased-



World. With our partnering, every visitor can network easily with the Who's Who of bioeconomy. Recent findings of biotechnological research are presented at the congress, a must for the knowledge-based industry. The programme contains numerous sessions with BiobasedWorld topics, from novel biocatalysts and bioprocesses to algae, speciality chemicals and biorefineries in general.

### Strategic impulses

Thursday, 18 June is dedicated to European Bioeconomy and HORIZON 2020. Experts from the European Commission, industry and trade associations will take a stand on the situation in the member states and discuss which impulses to expect from the new research strategy.

# Bio-based world

**Greeting** AICHEMA is not only the world forum for chemical engineering, but has always been the interface between the process industries and biotechnology. So what better event to attend when industrial biotech is your concern?



It is common knowledge that the bioeconomy is growing, but you rarely come into close contact with all the aspects of this fairly young industrial sector. At AICHEMA's BiobasedWorld, the bioeconomy becomes visible and tangible, the meeting point for industrial biotechnology.

Here, you will have the opportunity to experience what the end-user will seldom see: biobased economy in the making. BiobasedWorld covers all aspects from ideas for innovative bioprocesses, to technical equipment for building a complete production plant. We even have the final products, too.

Whether you are a technology provider, an equipment manufacturer, a project developer, a scientist, an investor or simply a curious person, we welcome you to Frankfurt to be part of the BiobasedWorld.

**Marlene Etschmann**  
Project leader BiobasedWorld  
DECHEMA Ausstellungs-GmbH

## › QUICK FACTS

### Highlights

- › BiobasedWorld
- › Exhibition & Congress
- › Expert round tables and forums

### Contact

Tel: +49 69 7564 -100  
exhibition@dechema.de  
www.achema.de



Frankfurt am Main · 15 – 19 June 2015

# ACHEMA 2015

- World Forum and Leading Show for the Process Industries
- 3,800 Exhibitors from 50 Countries
- 170,000 Attendees from 100 Countries

Be informed.

Be inspired.

Be there.

[www.achema.de](http://www.achema.de)